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Abstract A series of derivatives of the amphipathic proline-rich sweet arrow peptide (SAP) were 
covalently linked to antisense oligonucleotides designed to inhibit Renilla luciferase gene. 
Oligonucleotide-peptide conjugates carrying lysine (Lys) and ornithine (Orn) residues were prepared 
using the stepwise approach by assembling first the peptide sequence followed by the assembly of the 
DNA molecule. The resulting Lys, Orn-conjugates were transformed to the corresponding arginine (Arg) 
and homoarginine (HArg) oligonucleotide-peptide conjugates by reaction with O-methylisourea. The 
introduction of the SAP peptide at 3’-termini of a phosphorothioate oligonucleotide did not affect the 
ability to inhibit gene expression when transfected with lipofectamine. But, these conjugates were not 
able to enter cells without transfecting agent. Further studies using SAP peptide as a transfection agent 
showed promising results for the conjugates carrying the ornithine SAP peptide.  All conjugates showed 
high duplex stabilities.  
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Introduction 
 
Cell penetrating peptides (CPPs) are considered to be promising delivery agents because they efficiently 
translocate across the plasma membrane being able to enter in the cells [1, 2]. These CPPs contain 
domains of less than 20 amino acids and are highly rich in basic residues. This process of translocation 
across the cell membrane was demonstrated for the first time when the 86-mer trans-activating 
transcriptional activator, Tat protein, was internalized by cells [3-5]. Since then, researchers have been 
able to synthesize different and novel peptides or CPPs demonstrating this property of translocation; for 
instance, transportan [6], synthetic polyarginines [7] or TAT peptide [8]. To date, many modifications 
have been made in order to synthesize and optimize new CPPs as cellular delivery agents and introduce a 
variety of intracellular cargoes that have been transported by CPPs like liposomes [9], polymers [10], 
DNA [11] or nanoparticles [12-14].  
Recently, Giralt et al. described a new family of amphipathic peptides showing moderate ability to cross the 
cell membrane in addition to the absence of a cytotoxic effect at high concentrations [12-17]. This proline-rich 
peptide, called sweet arrow peptide, (SAP) whose sequence is (ValXLeuProProPro)3 (where X = His, Arg or 
Lys (K), respectively) is made up of 50% proline residues, is water-soluble and contains three positively 
charged X residues favoring interaction with phospholipids anionic polar heads. After various cellular uptake 
experiments, it was found that two different SAP peptide families (with X = Arg and Lys) could translocate 
human cell membranes. The positively charged and the amphipathic characteristics of SAP peptides may be of 
interest for the delivery of negatively charged oligonucleotides in gene silencing experiments.  
Oligonucleotides (ODNs) are important biomolecules involved in gene therapy [18, 19]. However, the activity 
of these compounds in vivo are compromised due to several factors like low stability against exonucleases, 
endonucleases present in serum [20].  Furthermore, delivery into cells is one of the bottlenecks encountered 
during the use of oligonucleotides in gene therapy.  This is primarily due the fact that these compounds are 
large and negatively charged.  
As a part of our ongoing interest in the development of chemically modified DNA [21] and siRNAs [22- 24] to 
inhibit gene expression, we became interested on the use of CPP for improving cellular uptake of 
oligonucleotides conjugates. Some authors have already described the attachment of use of CCP for delivery of 
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oligonucleotides [25]. Although the most common method for the use of CPP for tranfection of 
oliognucleotides is by using complexes (polyplexes and lipoplexes) thereby taking advantage of the 
electrostatic interaction of charged oligonucleotides [25], their stabilities could be compromised. In order to 
obtain more stable complexes and enhance resistance to the nuclease degradation of oligonucleotides, the use 
of a covalent linkage between CPPs and oligonucleotides has become an interesting alternative in overcoming 
the use of non-covalent methods which also has obtained promising biological results [26]. However, from a 
synthetic point of view, combining oligonucleotide chemistry with peptide chemistry covalently proves to be 
challenging. Surprisingly, the use of CPP-based delivery of antisense oligonucleotides has few references in 
literature [26-28]. Related to this field, promising results in nuclear delivery efficiencies were achieved for 
phosphorodiamidate morpholino oligomers (PMOs) that were conjugated to different CPPs such as Tat48-60 
(Tat), oligoarginine (R9F2) and the 6-aminohexanoic-spaced oligoarginine ((R-Ahx-R)4), obtaining better 
transfection efficiencies for the last conjugate [28]. 
In the present study, we looked into the possibility of obtaining new CPP-oligonucleotide conjugates 
combining the proline-rich SAP peptides with antisense oligonucleotides. Recently, our research group has 
succesfully used this strategy with the synthesis of several CPPs linked to oligonucleotides through the 
stepwise approach [21]. In this study, we will describe on the conjugation of amphipathic proline-rich SAP 
peptides [(ValXLeuProProPro)3, where X = Lys, Ornithine (Orn), Homo-arginine (HArg) and Arginine (Arg), 
respectively] with DNA sequences using this covalent strategy where spacers of different lengths make up the 
formation of a covalent conjugate between the cargo and the 3’-termini of the oligonucleotides. This strategy 
was used to obtain an oligonucleotide phosphorothioate designed to inhibit the Renilla luciferase gene [21, 29] 
carrying the aformentioned SAP peptides and the ability of these conjugates to inhibit gene expression was also 
evaluated in cells. The use of proline-rich peptides as non-viral vectors in cell transfection of plasmid DNA on 
solid lipid nanoparticles has been recently reported [30]; however to the best of our knowledge, it would be the 
first time that SAP peptide in combination of antisense oligonucleotides in both covalent and electrostatic 
aproaches is described for inhibition of gene expression.   
 
Experimental section 
 
Materials and methods 
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Protected amino acids were obtained from Novabiochem, Merck Chemicals (UK), and Bachem Gmbh 
(Germany). Poly(ethyleneglycol)-polystyrene resin (PEG-PS) was purchased from PerSeptive 
Biosystems, Inc. (USA). Coupling reagents: Benzotriazol-1-yloxytris(pyrrolidino)phosphonium 
hexafluorophosphate (PyBOP) were purchased from Sigma-Aldrich (USA) and 1-hydroxybenzotriazole 
(HOBt) were purchased from Albatros Chem Inc., Montreal, Canada. Solvents: Solvents for peptide 
synthesis and RP-HPLC equipment were obtained from Carlo Erba (Spain). Solvents for oligonucleotide 
synthesis were purchased from Applied Biosystems (USA). Trifluoroacetic acid (TFA), 
dimethylformamide (DMF), piperidine and N,N-diisopropylethylamine (DIEA) were purchased from 
Sigma-Aldrich (USA); dichloromethane (DCM) was purchased from Panreac (Spain). All commercial 
reagents and solvents were used as received. Semipreparative RP-HPLC was performed on a Waters 
(Milford, MA) chromatography system using Symmetry C18 (3 × 10 cm, 5 µm) columns. Analytical RP-
HPLC was performed using a XBridge OST C18 2.5 µm column. Compounds were detected by UV 
absorption at 260 nm. Mass spectra were recorded on a MALDI Voyager DE RP time-of-flight (TOF) 
spectrometer (Applied Biosystems, Framingham). Two different matrix were used: THAP (2,4,6-
trihydroxiacetophenone: 10 mg/mL in ACN:H2O 1:1 v/v, 0.1% TFA); CA (ammonium citrate: 50 mg/mL 
in H2O and SA (sinapinic acid: 10 mg/mL in ACN:H2O 1:1 v/v, 0.1% TFA). HPLC conditions: 
Conditions for semipreparative HPLC: HPLC solutions were solvent A: 5% acetonitrile (ACN) in 100 
mM triethylammonium acetate (TEAA), pH 6.5 and solvent B: 70 % ACN in 100 mM triethylammonium 
acetate (pH 6.5). Column: PRP-1 (Hamilton) 250x 10 mm. Flow rate 3 ml/min linear gradient from 15 to 
100% in B (DMT on) and 0 to 50% in B (DMT off) were used with UV detection at 260 nm. Conditions 
for analytical HPLC: HPLC solutions were solvent A: 5% acetonitrile (ACN) in 100 mM 
triethylammonium acetate (TEAA), pH 6.5 and solvent B: 70 % ACN in 100 mM triethylammonium 
acetate (pH 6.5). Column: XBridge OST C18 2.5 µm. Flow rate 1ml/min linear gradient from 0 to 50% in 
B (DMT off) were used with UV detection at 260 nm. 
 
Synthesis of SAP-oligonucleotide conjugates  
 
Solid support 3 was treated with DCM (4 x 30 sec); TFA:DCM (2:3, v/v; 1 x 1 min; 1 x 30 min); DCM (4 
x 30 sec); DIPEA:DCM (1:19, v/v; 3 x 1 min) and DCM (4 x 30 sec). Then, the modified succinate unit 
was reacted with solid support 3 using the following mixture: PyBOP (5.0 eq), DIPEA (10.0 eq), acid (5.0 
eq) for 2 hours at room temperature. This mixture was previously pre-activated in DMF and introduced 
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later on the solid support. The solid support was washed with DMF (4 x 30 sec), DCM (4 x 30 sec), DMF 
(4 x 30 sec), Ac2O:DIPEA (500 µL : 900 µL) in DMF (10 min); DMF (4 x 30 sec) and DCM (4 x 30 sec). 
Then, the solid support was split into two parts, and each one was washed with DCM (4 x 30 sec) and 
treated with TFA:DCM (2:3, v/v; 1 x 1 min; 1 x 30 min). Solid supports were washed with DCM (4 x 30 
sec); DIPEA:DCM (1:19, v/v; 3 x 1 min) and DCM (4 x 30 sec).  
Route A: The peptide with a N-terminal Boc (ValLysLeuProProPro)3 was prepared by standard “Boc-
Chemistry” solid-phase protocols yielding the solid-support 4. The side chain of lysine was protected with 
Fmoc group 
Route B: The peptide with N-terminal Boc (ValOrnLeuProProPro)3 was prepared by standard “Boc-
Chemistry” solid-phase protocols yielding the solid-support 7. The side chain of ornithine was protected 
with Fmoc group.  
Then, the N-Boc group from resins 4 and 7 were deprotected with a mixture of TFA:DCM (2:3, v/v; 1 x 1 
min; 1 x 30 min) and subsequently washed with DCM (4 x 30 sec); DIPEA:DCM (1:19, v/v; 3 x 1 min) 
and DCM (4 x 30 sec). The resins were split into two parts and trityl derivates 10-12 were introduced in 
using the same method as the respective amino acids (PyBOP, HOBt, DIPEA in DMF at room 
temperature). After an acetylation reaction, we obtained the desired Trityl-O-SAP peptides 5 and 8. The 
functionalization of the resulting trityl-peptide solid supports was determined by measuring the 
absorbance of the trityl cation released from the solid-support upon acid treatment.  
Then, trityl-peptide solid supports 5 and 8 were transferred directly to a DNA synthesizer (DMT on). 
After assembling the corresponding sequences (Dickerson-Drew dodecamer and phosphorothioate 
oligonucleotide), the resulting solid supports were treated with ammonia solution (32%) and the 
corresponding modified oligonucleotides were desalted (Sephadex, NAP-10) and purified by semi-
preparative reverse phase HPLC. DMT group was removed by a 30 min treatment with 80% acetic acid 
and removal of the acetic acid by extraction with ether. Finally, the desired oligonucleotide-peptide 
conjugates 6 and 9 were obtained after desalting (Sephadex, NAP-10). SAP- antisense phosphorothioate 
conjugates 6c and 9c were obtained by DNA precipitation protocols (see below) instead of using 
Sephadex. 
 
DNA precipitation protocols 
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DNA conjugates were transfered to a container where it fills one fourth the total volume (a 500 µL tube 
should have no more than 125 µL of DNA). We added one tenth volume of sodium acetate buffer to 
equalize ion concentrations. Then, two volumes of cold 100% ethanol were added. Mixtures were cooled 
at -20 ºC for at least one hour. Finally, we centrifugated the samples for 15 minutes at 4 ºC in a 
microcentrifuge and remove supernatants. We evaporated the remaining ethanol in a 37 ºC water bath. 
 
Introduction of the guanidinium groups.  
 
SAP-oligonucleotide conjugates 6 and 9 (1.5 OD, approx.) were treated with a solution (125 μL) and 
were prepared as follows: O-methylisourea chloride (100 mg) in water (100 μL) and ammonia (32%; 125 
μL). Reaction mixtures were heated at 55 ºC overnight. The solvent was then removed and the respective 
conjugates were desalted (Sephadex, NAP-5). SAP-oligonucleotide conjugates 13 and 14 were obtained 
and were checked using analytical HPLC. 
 
Thermal denaturation experiments 
 
Optical measurements were carried out on a Jasco V-650 spectrophotometer. Prior to the experiments, the 
SAP-oligonucleotide conjugates (each at a final concentration of 2.2 µM to 3.7 µM (approx)), were 
mixed in 50 mM NaCl, 10 mM sodium phosphate buffer, pH 7.0 conditions. A heating–cooling–heating 
cycle in the 20 to 90 ºC temperature range was applied. Tm values were determined from the maxima of 
the first derivative plots of absorbance versus temperature. 
  
Cell culture  
 
SH-SY5Y cells were cultured at 37 ºC, 5% CO2 in Dulbecco’s Modified Eagle’s Medium (DMEM; 
GIBCO) supplemented with 10% fetal bovine serum. Cells were regularly passaged to maintain 
exponential growth. Twenty-four hours before transfection at 50-80% confluency, cells were trypsinized 
and diluted 1:5 with fresh medium (1-3 x 105 cells/mL) and transferred to 24-well plates (500 µL per 
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well). Two luciferase plasmids, Firefly luciferase (pGL3) and Renilla luciferase (pRL-TK) (Promega), 
were used as reporter and as control, respectively. 
 
Transfection of SAP-oligonucleotide phosphorothioate conjugates using Lipofectamine 2000.   
 
Renilla and Firefly luciferase vectors (0.1 µg and 1.0 µg per well, respectively), unmodified and modified 
SAP- oligonucleotide phosphorothioate conjugates (6c, 6d, 9c, 9d, 13c and 14c, respectively; 60 nM per 
well), and a scrambled oligonucleotide (Scr; 60 nM per well) was transfected into the cells using 
Lipofectamine 2000 (Invitrogen) at 6.5 μg/ mL as described by the manufacturer for adherent cell lines. 
The final volume was 600 µL per well. The cells were harvested 24 hours after transfection and lysed 
using a passive lysis buffer (100 µL per well) according to the instructions from the Dual-Luciferase 
Reporter Assay System (Promega). The luciferase activities of the samples were measured using a 
MicroLumaPlus LB 96V Luminometer (Berthold Technologies) with a 2 second delay time and an 
integrate time of 10 seconds. The following volumes were used: 20 µL of sample and 30 µL of each 
reagent (Luciferase Assay Reagent II and Stop & Glo Reagent). The inhibitory effects generated by SAP-
oligonucleotide phosphorothioate conjugates were expressed as normalized ratios between the reporter 
GL3 (firefly) luciferase gene and the control RL (Renilla) luciferase gene. 
 
Transfection of SAP- oligonucleotide phosphorothioate conjugates in the absence of Lipofectamine 2000.   
 
Renilla and Firefly luciferase vectors (0.1 µg and 1.0 µg per well, respectively) were transfected into the 
cells using Lipofectamine 2000. Cells were incubated with the plasmids for 5 hours. The medium was 
discarded and the cells were washed with PBS. Then, 500 µL of fresh medium was added to each well. 
Finally, 100 µL of SAP-oligonucleotide phosphorothioate solutions (164.4 µM, 14.1 µM, 57.3 µM, 15.4 
µM, 23.6 µM and 64.8 µM for 6c, 6d, 9c, 9d, 13c and 14c, respectively in PBS) was added to each well 
(300 nM per well). Thirty-six hours after transfection, cell lysates were prepared and analyzed using the 
Dual-Luciferase Reporter Assay System as described above. 
 
Transfection of SAP-oligonucleotide phosphorothioate conjugates using SAP peptide as a transfection 
agent.  
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Renilla and Firefly luciferase vectors (0.1 µg and 1.0 µg per well, respectively) were transfected and cells 
were incubated following the same procedure as described before. The medium was discarded and the 
cells were washed with PBS. Then, 500 µL of fresh medium was added to each well. Then, 100 µL of 
SAP-oligonucleotide phosphorothioate conjugates with SAP peptide forming polyplexes in PBS were 
added to each well (150 nM and 300 nM per well) which were previously incubated at 37 ºC for 45 
minutes.  Thirty-six hours after transfection, cell lysates were prepared and analyzed using the Dual-
Luciferase Reporter Assay System as described above. 
 
Transfection of unmodified oligonucleotide phosphorothioate and SAP peptide.  
 
Renilla and Firefly luciferase vectors (0.1 µg and 1.0 µg per well, respectively) were transfected and cells 
were incubated following the same procedure as described before. The medium was discarded and the 
cells were washed with PBS. Then, 500 µL of fresh medium was added to each well. Then, 100 µL of 
polyplexes in PBS at different concentrations of SAP peptide (20 µM, 30 µM, 40 µM and 50 µM) were 
added to each well (150 nM and 300 nM per well).  
 
Gel shift assay 
 
Unmodified oligonucleotide phosphorothioate sequence, wt (0.5 µg) was mixed with increasing 
concentrations of SAP peptide, giving rise to SAP peptide: oligonucleotide molar ratios ranging from 1.2 
to 10. Complexes were analyzed by electrophoresis on a 20% polyacrylamide gel at 150V for 5 hours in 
TBE buffer. Picture were taken in Fujifilm LAS-1000 Intelligent Dark box II using IR LAS-1000 Lite 
v1.2 
 
Results and discussion 
 
Synthesis of SAP-oligonucleotide conjugates 
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The conjugation of CPPs to various ODNs can be performed by two different strategies: 1) the non-
covalent strategy in which peptides are able to condense with DNA or RNA molecules involving 
formation of complexes [25] and 2) the covalent strategy that involves the formation of a covalent 
conjugate between the cargo and the carrier peptide. This strategy can offer several advantages for in vivo 
applications such as the advantage of being well-defined molecular entities, obtaining better control of the 
stoichiometry of the CPP-cargo and possible improvement in the stability of the conjugate.    
The strategy followed for the synthesis of SAP-oligonucleotide conjugates is outlined on Figure 1. It is 
well known that there is a relationship between the lysine ε-amine group and ornithine δ-amine group 
with their respective homo-arginine (HArg) and arginine (Arg) amino acids. Taking into account the SAP 
peptide structure (ValXLeuProProPro)3, the stepwise approach was used in order to synthesize the SAP-
oligonucleotides conjugates (1) in their amine form (where X = lysine (Lys) and ornithine (Orn), 
respectively) (Fig. 1, Step A). To this end, Boc-amino acids were used and the side chains of lysine and 
ornithine were protected with the base labile trifluoroacetyl (Tfa) and fluorenylmethoxycarbonyl (Fmoc) 
groups, respectively. The first amino acid was linked to the solid support by using the 6-
aminohexylsuccinyl linker [21]. All together allow the removal of the side chain protecting groups and 
the liberation of the peptide from the solid support with an ammonia treatment used in oligonucleotide 
synthesis. However, introducing the three guanidinium groups (Fig. 1, Step B) is not straightforward. It 
has been described the use of the di-Fmoc-derivative of arginine in a stepwise protocol [31] but this 
derivative is not commercially available. Post-synthetic approaches have been also described [32, 33]. 
Recently, our research group reported the synthesis of phosphorothioate conjugates containing different 
residues of homo-arginines through post-synthetic approach according to the literature [24]. Following 
this strategy, we were able to introduce the corresponding guanidinium groups (where X’= homo-arginine 
and arginine, respectively) yielding the respective SAP-oligonucleotide conjugates (2) (Figure 1, Step B).  
In order to demonstrate our proposed strategy and the stability of the SAP-oligonucleotide conjugates, the 
self-complementary Dickerson-Drew dodecamer [34] sequence (5’-CGCGAATTCGCG-3’; Sequence A) 
was used as a model sequence. The synthesis of the conjugate 1 began with commercially available 
poly(ethyleneglycol)-polystyrene (PEG-PS, 3) (Perseptive Biosystems, 0.19 mmol/gr) as starting 
material. The first spacer was introduced into the resin and then was split equally into two parts: a lysine 
residue was introduced (Route A) whereas ornithine was introduced (Route B) thereby obtaining the 
appropriate peptides 4 and 7 by standard “Boc and Fmoc chemistry” solid-phase protocols whose peptide 
  11
sequences were (ValLysLeuProProPro)3 and (ValOrnLeuProProPro)3, respectively. The last Boc group 
was then removed and the resulting free amines were reacted with two spacer-trityl derivatives (10 and 
11), which were obtained in accordance with the literature [35]. The trityl modified solid-supports (5 and 
8) were transferred directly to a DNA synthesizer and the respective phosphoramidites were coupled to 
the self-complementary sequence model 5’-CGCGAATTCGCG-3’ (Dickerson-Drew dodecamer) at the 
3’-position. The solid supports were then cleaved with an ammonia solution (32%) at 55 ºC overnight and 
the corresponding SAP-oligonucleotide conjugates were obtained in their amine form. The conjugates 
were purified according to DMT on based protocols (Fig. 2) and the resulting SAP-oligonucleotide 
conjugates (6a, 6b, 9a and 9b) were fully characterized by MALDI-TOF mass spectrometry 
(Supplementary material, Table 1S).   
The modification of the amine group to the guanidinium moiety in the peptide sequence was carried out 
using a post-synthetic modification approach using a freshly prepared solution of O-methylisourea, 
yielding the expected SAP-guanidino conjugates 13a, 13b, 14a and 14b, respectively (Fig. 3). The 
guanidynilation reaction was quantitative yielding the respective conjugates in pure form and without 
further purification. The resulting conjugates were confirmed using analytical HPLC chromatography and 
MALDI-TOF mass spectrometry (Supplementary material, Table 1S). 
 
Synthesis of SAP-oligonucleotide phosphorothioate conjugates and biological evaluation 
 
Next, according to the strategy described before, SAP-oligonucleotide conjugates (6c, 6d, 9c, 9d, 13c, 14c) 
were synthesized and evaluated in gene silencing experiments. We recently described an oligonucleotide 
phosphorothioate sequence that is active in inhibiting Renilla luciferase gene  (5’- 
AGGTCTTGTTTCCTTTGC-3’; Sequence B) when is linked to polylysine and polyhomoarginine peptides at 
3’-termini [21]. Thus, a series of SAP peptides ((ValXLeuProProPro)3 with X = Lys, Orn, HArg and Arg) were 
covalently combined with the aforementioned Renilla phosphorothioate sequence which was designed and 
evaluated as potential antisense oligonucleotides for inhibiting the Renilla luciferase gene. SAP-
phophorothioate conjugates (6c, 6d, 9c, 9d, 13c and 14c, respectively) were obtained from the previous solid-
suports 5b and 8b following the stepwise solid-phase and post-synthetic modification methods described for 
the Dikerson-Drew dodecamer. All conjugates were fully characterized by MALDI-TOF mass spectrometry 
(see Supplementary material, Table 1S), except for 9d in which we were not able to detect the expected mass 
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by spectrometry. In order to determine whether we had conjugate 9d in our hands, all conjugates were analyzed 
by denaturing polyacrylamide gel electrophoresis (PAGE) in 20% polyacrylamide, 8M urea (see 
Supplementary material, Fig. 2S). As expected, the conjugate 9d showed similar retention than the rest of the 
SAP-antisense  phosphorothioate conjugates.  
The inhibitory properties of the resulting SAP-antisense phosphorothioate conjugates were analyzed in SH-
SY5Y cells. The cells were co-transfected with two luciferase plasmids (Renilla and firefly; target and internal 
control, respectively), SAP-antisense phosphorothioate conjugates (6c, 6d, 9c, 9d, 13c and 14c at 60 nM), a 
scrambled sequence (Scr)  and the same scramble sequence conjugated with SAP peptide containing ornithine 
using commercial Lipofectamine 2000. We also included the antisense phosphorothioate sequence without 
SAP peptide (wt). The luciferase activities were measured by using a luminometer twenty-two hours after 
transfection.  The results, showing Renilla luciferase activity normalized to firefly luciferase, are shown on Fig. 
4. Interestingly, all SAP-oligonucleotide conjugates demonstrated gene knockdown activities (71%, 62 %, 
81%, 82%, 77% and 81% for 6c, 6d, 9c, 9d, 13c and 14c, respectively) similar to the phosphorothioate 
sequence with no peptide (82% for wt). These results confirm that the SAP peptide as a modification does not 
disrupt antisense activity nor does it interfere with cellular activity.  
Next, we carried out transfection experiments in the absence of lipofectamine in order to know the capacity of 
our conjugates to impart cellular uptake. After incubating the two luciferase plasmids for five hours, the cell 
medium was discarded and the cells were incubated again with a fresh medium; the SAP-antisense 
phosphorothioate conjugates (6c, 6d, 9c, 9d, 13c and 14c) and the phosphorothioate sequence without peptide 
(wt) at 300 nM.  The luciferase activities were measured thirty-six hours after transfection. Unfortunately, the 
conjugates were not able virtually to penetrate SH- SY5Y cells by themselves (3%, 3 %, 3%, 2 %, 1% and 0% 
knockdown of Renilla expression at 300 nM for 6c, 6d, 9c, 9d, 13c and 14c, respectively) (Supplementary 
material, Fig. 3S). 
 
Transfection efficiencies wih unmodified ASO phosphorothioate and SAP peptide forming complexes 
 
The ability of certain cationic peptides to condense DNA, specifically arginine-rich peptides for 
improving DNA delivery has been described [36]. The formation of non-covalent complexes between 
CPPs and oligonucleotides has been reported by several research groups and the complex formation has 
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been also characterized using different biophysical techniques [37]. Recently, the ability of SAP peptide 
to translocate human cell membranes has been reported. This property is in agreement with the inherent 
properties to the amphipathic helix character of the SAP peptide when arginine is present in the peptide 
sequence thereby being most efficient for cellular uptake process [15, 30].  Furthermore, due to its non-
viral origin, amphipathic character and solubility in water, SAP peptide could a priori present several 
advantages as a transfection agent taking advantage of its positive charges.  
First, we evaluated the amount of required SAP peptide ((ValArgLeuProProPro)3) in which the 
unmodified antisense phosphorothioate is able to form complexes. We performed a gel shift assay to 
evaluate the amount of SAP peptide that efficiently interacted with an unmodified phosphorothioate 
oligonucleotide, wt (Supplementary material, Fig. 1S). Several concentrations of the peptide were added, 
from 1.2-fold molar excess of the peptide compared with wt oligonucleotide to a 10-fold molar excess. 
We observed that SAP peptide was able to retard completely the oligonucleotide phosphorothioate, wt at 
a molar ratio of 10:1, as shown in Fig. 1S, lane 7.  
To assess whether the interaction of the SAP peptide with the oligonucleotide phosphorothioate, as shown 
in the gel shift assay, was able to impart cellular uptake in the absence of a transfection agent, we 
performed the experiments described before in SH-SY5Y cells using pGL3 as a reporter gene. The molar 
ratios tested for gene knockdown were 4:1, 6:1, 8:1 and 10:1 respectively (peptide:antisense 
oligonucleotide). Interestingly, we observed that the majority of the complexes had gene specific 
inhibitory properties at 300 nM thereby obtaining promising results (around 40% of inhibition efficacy in 
all cases), except for the first case (4-fold molar excess of SAP peptide) which its activity was detrimental 
(Fig. 5). This is not surprising according to the SDS-PAGE where we clearly observed the complex 
formation using at least 6-fold of peptide. A scramble sequence (Scr) was also used in this study as a 
control to establish that the gene knockdown was specific. This sequence was only complexed with the 
peptide at a 6:1 M ratio yielding no effect on luciferase expression. Experiments at 150 nM were also 
performed. As expected, we clearly observed that SAP peptide and unmodified phosphorothioate (wt) 
complexes significantly decreased the luciferase activity in a concentration-dependent manner (see 
Supplementary material, Fig. 4S). 
 
Transfection efficiencies wih SAP-oligonucleotide phosphorothioate conjugates and SAP peptide forming 
complexes 
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Next we studied the use of the SAP peptide as transfecting agent for the SAP-antisense conjugates. To 
this end, we analyzed the gene knockdown effect in SH-SY5Y cells by using SAP-antisense conjugates 
(6c, 6d, 9c, 9d, 13c and 14c, respectively) along with SAP peptide acting as a transfecting agent in a 6-
fold molar excess (peptide:SAP-antisense conjugate). We subjected the same protocol as described before 
for unmodified antisense oligonucleotide to perform in vitro transfections at 150 nM. Notably, we 
observed an improvement in the activities inhibition when SAP peptide was used as a transfection agent. 
The majority of SAP-antisense conjugates in combination with SAP peptide were able to inhibit Renilla 
gene expression thereby slightly improving the activities compared to the experiments previously 
described without using any transfection agent (11%, 20%, 26%, 27%, 14% and 26% for 6c, 6d, 9c, 9d, 
13c and 14c, respectively) (Supplementary material, Fig. 5S-A). Although the majority of the conjugates 
showed similar activities to those obtained with unmodified antisense:SAP polyplexes, surprisingly, we 
found that conjugates containing ornithine and arginine in their peptide sequence (9c, 9d and 14c) had 
slightly better transfection efficiencies than conjugates containing lysine and homo-arginine (6c, 6d and 
13c).  
We also evaluated the inhibitory properties of SAP-antisense phosphorothioate conjugates using SAP 
peptide as a transfection agent at 300 nM and 6:1 molar (peptide: SAP-antisense conjugate) ratio. 
Surprisingly, only SAP-antisense conjugates containing ornithine (22% and 18% for 9c and 9d, 
respectively) were able to knockdown gene expression (Supplementary material, Fig. 5S-B) whereas the 
activities in gene-knockdown expression for SAP-antisense conjugates containing lysine, homo-arginine 
and arginine (6c, 6d, 13c and 14c, respectively) were detrimental (see Supplementary material, Fig. 5S). 
To our surprise, transfections carried out at 300 nM did not keep a typical dose-response behavior 
compared to the experiments performed at 150 nM as we observed previously with polyplexes containing 
unmodified antisense oligonucleotide (wt). These results might be explained in light of the potential 
cytotoxic effects imparted by some conjugates in combination with the peptide at high concentrations on 
the SH-SY5Y cells thereby suggesting that gene knockdown expression might be compromised at 300 
nM.  
Finally, in view of all these results, we compared the effect of SAP peptide as a transfection agent to 
lipofectamine in the same gene knockdown experiments and cell line. SAP-antisense oligonucleotide 
conjugates containing ornithine and arginine (9c, 9d and 14c) were chosen to examine the corresponding 
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transfection efficiencies, discarding the rest of the conjugates. As expected, experiments carried out with 
lipofectamine gave better results in gene knockdown effects than SAP peptide in our hands at both 60 nM 
and 150 nM (Fig. 6). In this case we also observed that the gene inhibitory properties of the conjugates 
when SAP peptide is used as transfecting agent were better at lower oligonucleotide concentration (60 
nM) than at higher concentration (150 nM). This effect was not seen when transfection was done with 
Lipofectamine. These data indicates that the formation of efficient transfecting polyplexes of conjugates 
with the SAP peptide is dependent of the concentration of both peptide and oligonucleotide conjugate 
and, for some reason, at higher conjugate concentration the polyplexes formed may not be efficient for 
cell transfection.  But, at lower concentration of oligonucleotide conjugate the polyplexes formed are 
efficient for transfection. Best results were obtained at 60 nM with the ornithine containing conjugates 
(62% inhibition 9c, 67% inhibition 9d). In these conditions the molar ratio between peptide and 
oligonucleotide conjugate is 6:1 while in the lipofectamine experiments lipofectamine is used at 
approximately 100 molar excess and reaches 81-82% inhibition.     
 
Thermal denaturation experiments 
 
The duplex stabilities of conjugates 6, 9, 13 and 14 (phosphate and phosphorothioate conjugates, respectively) 
were measured using the following conditions: 50 mM NaCl, 10 mM sodium phosphate buffer, pH 7.0 (Table 
1). Under these conditions, all phosphate conjugates (amine and guanidinium series, respectively) showed 
higher Tm values than the unmodified oligonucleotide (Tm = 44 ºC for the Dickerson-Drew dodecamer). The 
higher stabilities were found in the lysine (ΔTm 12.4, 17.8 ºC) and ornithine (ΔTm 14.4, 14.8 ºC) conjugates. 
Duplexes carrying homoarginine (ΔTm 10.0, 12.2 ºC) and arginine (ΔTm 15.0, 7.0 ºC) were, in general, less 
stable. In the case of phosphorothioate conjugates the unmodified antisense oligonucleotide melted at 30.5 ºC; 
and most of the conjugates had a slight stabilization (ΔTm 1.5-3.4 ºC) except conjugate 9c that melted at a 
temperature slightly lower than the unmodified phosphorothioate (Tm = 29.9 ºC) . 
 
Conclusions 
 
We synthesized two different amphipathic rich-proline peptide (SAP) families covalently linked to 
oligonucleotides using spacers of different lengths between both biomolecules. In general, both SAP-
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oligonucleotides and SAP-antisense phosphorothioate conjugates containing lysine in their structure were 
obtained with a higher yield than the SAP-oligonucleotide conjugates containing ornithine. This difference in 
reactivity could be attributed to the existing side-reactions consisting of the premature and undesired removal 
of the Fmoc group caused by a primary amine of sufficient basicity like the amine group of ornithine present  
in the peptide resin [38]. The introduction of  guanidinium groups was carried out using post-synthetic 
approximation with better results and purity levels.  
Studies in the inhibition of gene expression showed that the introduction of the SAP peptide at 3’-position of an 
antisense oligonucleotide does not affect antisense activity. However, the cell uptake experiments that we 
carried out with the conjugates were compromised. This lack of activity could be attributed to a poor cellular 
uptake of SAP conjugates in absence of lipofectamine. Next, we carried out  gene-knockdown experiments 
using SAP peptide itself as a transfection agent due to its advantages as non-viral origin, amphipathic character 
and the absence of cytotoxic effects at high concentrations. SAP peptide was able to form polyplexes with the 
corresponding SAP-antisense conjugates, obtaining promising results for SAP-antisense conjugates containing 
ornithine in their peptide sequence. We also evaluated the effect of complexation between SAP peptide and 
unmodified antisense phosphorothioate sequence thereby also obtaining promising results of around 40% of 
gene expression inhibition at 300 nM. This first generation of conjugates complexed with amphipathic SAP 
peptide  represent a promising lead for future optimization in both antisense therapy and RNA interference. 
Finally, we measured the thermal stability of duplexes carrying SAP peptides and found there was a 
remarkable stabilization of the duplex induced by the presence of the positively charged peptide.  
 
 
Supporting Information 
 
Experimental procedures, HPLC chromatograms, MALDI-TOF mass spectrometry graphs, denaturing and 
naturing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), transfection results without 
using lipofectamine and dose-response experiments. 
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Fig. 1 Strategies for the synthesis of SAP-oligonucleotide conjugates in their amine (1) and 
guanidinium form (2) using stepwise approach (Step A) or post-synthetic approach (Step B) 
 
 
Oligonucleotide
 5'-CGCGAATTCGCG-3'
 5'-AGGTCTTGTTTCCTTTGC-3' 
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(Val X Leu Pro Pro Pro)
3
SAP peptide
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where X = Lysine, Ornithine
X' = Homo-Arginine, Arginine
spacer =
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Fig. 2 Stepwise synthesis of SAP-oligonucleotide conjugates containing lysine (6) and ornithine (9) 
n
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6a (n = 0; X = O); 6b (n = 3; X = O)
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Fig. 3 Guanydinylation reaction used for the synthesis of SAP-oligonucleotide conjugates 13 and 14 
 
3
Oligonucleotide
6a (X = Lys; Y = O; n = 0); 9a (X = Orn; Y =O; n = 0)
6b (X = Lys; Y = O; n = 3); 9b (X = Orn; Y = O; n = 3)
6c (X = Lys; Y = S; n = 3); 9c (X = Orn; Y = S; n = 3)
(Val X Leu Pro Pro Pro)
(Val X Leu Pro Pro Pro)
13a (X = HArg; n = 0); 13b (X = Arg; n = 0); 13c (X = HArg; Y = S; n = 3)
14a (X = HArg; n = 3); 14b (X = Arg; n = 3); 14c (X = Arg; Y = S; n = 3)
a
Reagents and Conditions: a. i. NH3(32%), O-methylisourea, H2O, 55 ºC, overnight; ii. Sephadex
Oligonucleotide
3
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Table 1. Melting temperatures of SAP-oligonucleotide conjugates carrying phosphodiester and 
phosphorothioate linkages. 
Sequence 
(5’->3’) 
SAP-DNA conjugate Tm (ΔTm)
a / ºC 
A 6a 56.4 (12.4) 
A 6b 61.8 (17.8) 
A 9a 58.4 (14.4) 
A 9b 58.8 (14.8) 
A 13a 54.0 (10.0) 
A 13b 56.2 (12.2) 
A 14a 59.0 (15.0) 
A 14b 51.0 (7.0) 
B 6c 32.0 (1.5) 
B 6d 33.9 (3.4) 
B 9c 29.9 (-0.6) 
B 9d 32.5 (2.0) 
B 13c 35.6 (3.1) 
B 14c 32.2 (1.7) 
A unmodified 44.0 
B wt, unmodified 30.5 
n.d. not determined; aΔTm is the difference between the melting temperature  
of the modified oligonucleotide minus the melting temperature of the corresponding  
unmodified oligonucleotide; Buffer conditions: 50 mM NaCl, 10 mM; sodium phosphate pH 7.0 
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Fig. 4 Gene-specific silencing activities for phosphorothiote oligonucleotides (wt, 6c, 6d, 9c, 9d, 
13c, 14c, Scr and Scr-Orn) (60 nM per well) targeting the Renilla luciferase mRNA expressed in 
SH-SY5Y cells. Transfection of antisense oligonucleotides was carried out by using Lipofectamine 
2000. Two scrambled sequences (Scr and Scr-Orn) gave no Renilla luciferase inhibition.      
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Fig. 5 Gene-specific silencing activities for unmodified phosphorothioate oligonucleotide (wt) with 
and without SAP-peptide (300 nM per well) targeting the Renilla luciferase mRNA expressed in SH-
SY5Y cells. The molar ratios tested for gene knockdown were 4:1, 6:1, 8:1 and 10:1 respectively 
(peptide:antisense oligonucleotide). Transfection of antisense oligonucleotide was carried out by using 
SAP peptide. Scrambled sequence (Scr) gave no Renilla luciferase inhibition. The bar named wt is 
the result of luciferase activity without using SAP peptide as transfecting agent.     
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Fig. 6 Gene-specific silencing activities for SAP-antisense oligonucleotide conjugates at 60 nM 
and 150 nM with lipofectamine and SAP peptide as transfection agents. The peptide/ antisense 
oligonucleotide molar ratio used was 6:1 targeting the Renilla luciferase mRNA expressed in 
SH-SY5Y cells. A scrambled sequence combined with SAP peptide in a 6:1 M ratio gave no 
Renilla luciferase inhibition (both at 60 nM and 150 nM). 
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Table 1S. MALDI-TOFF mass spectrometry 
 
Sequence 
(5’->3’) 
SAP-ODN 
conjugate 
MW (calc) MW (found) 
A 6a 5793 5800 
A 6b 5821 5824 
B 6c 7898 7909 
B 6d 8010 8033 
A 9a 5750 5752 
A 9b 5779 5783 
B 9c 7884 5969* 
B 9d 7968 n.d. 
A 13a 5919 5920 
A 13b 5947 5951 
B 13c 8046 8020 
A 14a 5887 5891 
A 14b 5877 5908 
B 14c 7995 5926* 
B Scr-Orn 7884 5935* 
A unmodified n.d n.d. 
B unmodified 5715 5720 
 
Sequence A (phosphate form): 5’-CGCGAATTCGCG-3’ 
Sequence B (phosphorothioate form): 5’- AGGTCTTGTTTCCTTTGC-3’ 
n.d. not determined; *the mass corresponds to the removal of the whole peptide and the two spacers 
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SAP-ODN conjugates. HPLC chromatograms and MALDI-TOFF mass spectrometry 
spectra 
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SAP-antisense phosphorothioate conjugates. HPLC chromatograms and MALDI-TOFF 
mass spectrometry spectra 
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Polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Fig. 1S. Native SDS-PAGE gel shift assay to analyze the ability of SAP peptide to form 
complexes with unmodified oligonucleotide phosphorothioate (wt). SAP peptide shows the 
highest propensity for the formation of the complex with the phosphorothioate oligonucleotide 
at a 10-fold molar excess of SAP 
 
 
 
Fig. 2S  7M urea PAGE of SAP-antisense phosphorothioate conjugates 
 
 
20 % Polyacrylamide, 8M urea gel electrophoresis of SAP-antisense phosphorothioate 
conjugates. The gel was stained with STAINS-ALL. Lane 1: SAP-antisense phosphorothioate 
6c; Lane 2: 6d; Lane 3: 9c; Lane 4:  9d; Lane 5: 13c; Lane 6: 14c 
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Cell Culture 
 
Fig. 3S Gene-specific silencing activities of antisense phosphorothioate oligonucleotide 
conjugates without lipofectamine at 300 nM oligonucleotide concentration 
 
 
Gene-specific silencing activities for unmodified phosphorothioate oligonucleotide (wt), and 
SAP-antisense phosphorothioate conjugates (6c, 15, 9c, 16, 13c and 14c; 300 nM per well) 
targeting the Renilla luciferase mRNA expressed in SH-SY5Y cells. Transfection of antisense 
oligonucleotides was carried out without using Lipofectamine 2000.  
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Fig. 4S Dose-response experiments of SAP: antisense phosphorothioate complexes at 150 
nM and 300 nM oligonucleotide concentration  
 
 
 
Gene-specific silencing activities for unmodified antisense oligonucleotide (wt) complexed with 
SAP peptide. The concentration of antisense oligonucleotide was 150 nM and 300 nM, 
respectively. The molar peptide: antisense oligonucleotide ratio used was 4:1, 6:1 and 10:1 
targeting the Renilla luciferase mRNA expressed in SH-SY5Y cells. Transfection was carried 
out using SAP peptide as transfecting agent. The bar wt represents the value of the luciferase 
activity without using SAP peptide as transfecting agent. A scramble sequence combined with 
SAP peptide in a 6:1 M ratio gave no Renilla luciferase inhibition.  
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Fig. 5S Gene-specific silencing activities for antisense phosphorothioate oligonucleotide 
conjugates using SAP peptide as a transfecting agent at a molar ratio of 6:1 (SAP peptide / 
oligonucleotide). 
 
A 
 
B 
 
Gene-specific silencing activities for phosphorothiote oligonucleotide conjugates (wt, 6c, 6d, 
9c, 9d, 13c, 14c and Scr-Orn) targeting the Renilla luciferase mRNA expressed in SH-SY5Y 
cells. Transfection of antisense oligonucleotides was carried out using SAP peptide as 
transfecting agent in a 6-fold molar excess (peptide:SAP-antisense conjugate) (A) Experiment 
was performed at 150 nM oligonucleotide concentration; (B) Experiment was performed at 300 
nM oligonucleotide concentration. Scrambled sequence (Scr-Orn) gave no Renilla luciferase 
inhibition.      
